NASDAQ:NOVN Novan (NOVN) Stock Price, News & Analysis → #1 election stock (From Porter & Company) (Ad) Free NOVN Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume12,600 shsAverage Volume602,421 shsMarket Capitalization$22,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Get Novan alerts: Email Address Ad Chaikin AnalyticsA.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. About Novan Stock (NASDAQ:NOVN)Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.Read More Ad Chaikin AnalyticsA.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.Get the name and ticker symbol for free - just click here. NOVN Stock News HeadlinesMay 1, 2024 | americanbankingnews.comStockNews.com Initiates Coverage on Novan (NASDAQ:NOVN)April 23, 2024 | americanbankingnews.comNovan (NASDAQ:NOVN) Research Coverage Started at StockNews.comMay 2, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. February 27, 2024 | wsj.comNovartis AGFebruary 16, 2024 | morningstar.comNovartis AG Registered SharesOctober 31, 2023 | morningstar.comNovartis AG Registered Shares NOVNSeptember 8, 2023 | bizjournals.comNovan reaches deals to sell assets in bankruptcy caseAugust 8, 2023 | msn.comFirm Retention Summary: NovanMay 2, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. August 3, 2023 | msn.comNovan (NOVN) Price Target Increased by 43.52% to 15.81July 17, 2023 | marketwatch.comNovan Shares Hit 52-Week Low After Bankruptcy DeclarationJune 1, 2023 | bizjournals.comNovan cuts 50% of its workforce to extend runwayJune 1, 2023 | msn.comNovan drops 13%, will reduce workforce by 50%May 31, 2023 | markets.businessinsider.comNovan To "Sharpen" Focus, Resources On Berdazimer GelMay 31, 2023 | finance.yahoo.comNovan Focuses Strategic Direction and Announces RestructuringMay 21, 2023 | fool.comNovan (NASDAQ: NOVN)May 17, 2023 | msn.comOppenheimer Maintains Novan (NOVN) Outperform RecommendationMay 16, 2023 | finance.yahoo.comNOVN: Counting Down to PDUFAMay 15, 2023 | finanznachrichten.deNovan, Inc.: Novan Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | markets.businessinsider.comNovan earnings: here's what Wall Street expectsMay 12, 2023 | msn.comEarnings Preview: NovanMay 12, 2023 | msn.comNovan Q1 2023 Earnings PreviewApril 20, 2023 | finance.yahoo.comNovan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDApril 3, 2023 | msn.comNovan's Return On Capital Employed OverviewMarch 23, 2023 | finance.yahoo.comNovan to Report Full Year 2022 Financial Results on March 30, 2023March 7, 2023 | finance.yahoo.comFDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024October 19, 2022 | reuters.comJPMorgan names Qian as Southeast Asia equity capital markets chief - ReutersSee More Headlines Receive NOVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novan and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2023Today5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NOVN CUSIPN/A CIK1467154 Webwww.novan.com Phone(919) 485-8080Fax919-237-9212Employees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,310,000.00 Net Margins-128.61% Pretax Margin-128.39% Return on Equity-700.28% Return on Assets-39.58% Debt Debt-to-Equity RatioN/A Current Ratio0.74 Quick Ratio0.72 Sales & Book Value Annual Sales$24.71 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / BookN/AMiscellaneous Outstanding Shares28,015,000Free Float27,651,000Market Cap$22,000.00 OptionableNot Optionable Beta-0.06 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Paula Brown Stafford M.P.H. (Age 58)Pres, CEO & Chairwoman Comp: $623.23kMr. John M. Gay CPA (Age 46)CFO, Principal Accounting Officer & Corp. Sec. Comp: $386.89kMr. John A. Donofrio Jr. (Age 56)Exec. VP & COO Comp: $602.51kDr. Carri Geer Ph.D.Sr. VP & CTODr. Tomoko Maeda-Chubachi M.B.A.M.D., Ph.D., Chief Medical OfficerKey CompetitorsNVN LiquidationNASDAQ:NOVNQStatera BiopharmaNASDAQ:STABScopus BioPharmaNASDAQ:SCPSHumanigenNASDAQ:HGENViewRayNASDAQ:VRAYQView All CompetitorsInsidersMachelle SandersSold 11,553 sharesTotal: $4,736.73 ($0.41/share)View All Insider Transactions NOVN Stock Analysis - Frequently Asked Questions Should I buy or sell Novan stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NOVN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NOVN, but not buy additional shares or sell existing shares. View NOVN analyst ratings or view top-rated stocks. How were Novan's earnings last quarter? Novan, Inc. (NASDAQ:NOVN) posted its quarterly earnings data on Monday, May, 15th. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.22. The firm earned $3.17 million during the quarter, compared to analyst estimates of $6.19 million. Novan had a negative net margin of 128.61% and a negative trailing twelve-month return on equity of 700.28%. During the same quarter in the previous year, the company earned ($0.71) EPS. What other stocks do shareholders of Novan own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL) and Organigram (OGI). When did Novan IPO? Novan (NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers. How do I buy shares of Novan? Shares of NOVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NOVN) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novan, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
